Cargando…
Targeting ADP-ribosylation as an antimicrobial strategy
ADP-ribosylation (ADPr) is an ancient reversible modification of cellular macromolecules controlling major biological processes as diverse as DNA damage repair, transcriptional regulation, intracellular transport, immune and stress responses, cell survival and proliferation. Furthermore, enzymatic r...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172630/ https://www.ncbi.nlm.nih.gov/pubmed/31176616 http://dx.doi.org/10.1016/j.bcp.2019.06.001 |
_version_ | 1783524291624566784 |
---|---|
author | Catara, Giuliana Corteggio, Annunziata Valente, Carmen Grimaldi, Giovanna Palazzo, Luca |
author_facet | Catara, Giuliana Corteggio, Annunziata Valente, Carmen Grimaldi, Giovanna Palazzo, Luca |
author_sort | Catara, Giuliana |
collection | PubMed |
description | ADP-ribosylation (ADPr) is an ancient reversible modification of cellular macromolecules controlling major biological processes as diverse as DNA damage repair, transcriptional regulation, intracellular transport, immune and stress responses, cell survival and proliferation. Furthermore, enzymatic reactions of ADPr are central in the pathogenesis of many human diseases, including infectious conditions. By providing a review of ADPr signalling in bacterial systems, we highlight the relevance of this chemical modification in the pathogenesis of human diseases depending on host-pathogen interactions. The post-antibiotic era has raised the need to find alternative approaches to antibiotic administration, as major pathogens becoming resistant to antibiotics. An in-depth understanding of ADPr reactions provides the rationale for designing novel antimicrobial strategies for treatment of infectious diseases. In addition, the understanding of mechanisms of ADPr by bacterial virulence factors offers important hints to improve our knowledge on cellular processes regulated by eukaryotic homologous enzymes, which are often involved in the pathogenesis of human diseases. |
format | Online Article Text |
id | pubmed-7172630 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71726302020-04-22 Targeting ADP-ribosylation as an antimicrobial strategy Catara, Giuliana Corteggio, Annunziata Valente, Carmen Grimaldi, Giovanna Palazzo, Luca Biochem Pharmacol Review ADP-ribosylation (ADPr) is an ancient reversible modification of cellular macromolecules controlling major biological processes as diverse as DNA damage repair, transcriptional regulation, intracellular transport, immune and stress responses, cell survival and proliferation. Furthermore, enzymatic reactions of ADPr are central in the pathogenesis of many human diseases, including infectious conditions. By providing a review of ADPr signalling in bacterial systems, we highlight the relevance of this chemical modification in the pathogenesis of human diseases depending on host-pathogen interactions. The post-antibiotic era has raised the need to find alternative approaches to antibiotic administration, as major pathogens becoming resistant to antibiotics. An in-depth understanding of ADPr reactions provides the rationale for designing novel antimicrobial strategies for treatment of infectious diseases. In addition, the understanding of mechanisms of ADPr by bacterial virulence factors offers important hints to improve our knowledge on cellular processes regulated by eukaryotic homologous enzymes, which are often involved in the pathogenesis of human diseases. Elsevier Inc. 2019-09 2019-06-06 /pmc/articles/PMC7172630/ /pubmed/31176616 http://dx.doi.org/10.1016/j.bcp.2019.06.001 Text en © 2019 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Catara, Giuliana Corteggio, Annunziata Valente, Carmen Grimaldi, Giovanna Palazzo, Luca Targeting ADP-ribosylation as an antimicrobial strategy |
title | Targeting ADP-ribosylation as an antimicrobial strategy |
title_full | Targeting ADP-ribosylation as an antimicrobial strategy |
title_fullStr | Targeting ADP-ribosylation as an antimicrobial strategy |
title_full_unstemmed | Targeting ADP-ribosylation as an antimicrobial strategy |
title_short | Targeting ADP-ribosylation as an antimicrobial strategy |
title_sort | targeting adp-ribosylation as an antimicrobial strategy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172630/ https://www.ncbi.nlm.nih.gov/pubmed/31176616 http://dx.doi.org/10.1016/j.bcp.2019.06.001 |
work_keys_str_mv | AT cataragiuliana targetingadpribosylationasanantimicrobialstrategy AT corteggioannunziata targetingadpribosylationasanantimicrobialstrategy AT valentecarmen targetingadpribosylationasanantimicrobialstrategy AT grimaldigiovanna targetingadpribosylationasanantimicrobialstrategy AT palazzoluca targetingadpribosylationasanantimicrobialstrategy |